Becker's Healthcare August 21, 2024
In a phase 3 trial spanning three years, weekly injections of tirzepatide reduced the risk of Type 2 diabetes by 94%, Eli Lilly said Aug. 20.
Tirzepatide, the active ingredient of diabetes drug Mounjaro and weight loss medication Zepbound, also led to an average weight loss of 22.9%.
About 1,030 adults who have prediabetes or are obese or overweight took the therapy for 176 weeks, and the drugmaker said its safety and tolerability profile was consistent with past research.
Mounjaro and Zepbound are glucagon-like peptide-1 receptor agonists (GLP-1) and glucose-dependent insulinotropic polypeptides (GIP).
Mounjaro and other GLP-1 medications approved for Type 2 diabetes might affect the growing prevalence of the condition — between 2012 and 2022,...
Today's Sponsors
Today's Sponsor